Jana K. Dammann de Chapto
Partner
Hamburg
jana.dammann@lw.com
+49.40.4140.30
PRACTICES
- Antitrust & Competition
- Economic Sanctions & Export Controls
- Litigation & Trial
INDUSTRIES
- Aerospace, Defense & Government Services
EDUCATION
- Dr. jur., University of Hamburg, 2007
- Second German State Exam, Higher Regional Court, Hamburg, 2007
- LLM, University of Miami School of Law, 2004
- First German State Exam, University of Hamburg, 2002
LANGUAGES SPOKEN
PROFILE
Dr. Jana Dammann de Chapto advises international clients on merger control and foreign investment control.
Jana, as a key member of a client’s deal team, navigates the increasingly complex competition, merger control, and foreign investment control landscape in the EU and globally. She represents clients from a full spectrum of industries before the European Commission, national regulatory agencies, as well as before the German and European courts.
Jana's commercial work draws on her earlier scholarly work on merger control at the University of Hamburg, her PhD on comparative antitrust law, and her work at the Max Planck Institute for Comparative and International Private Law. She regularly writes and speaks on foreign investment topics.
EXPERIENCE
Jana's representative experience includes advising:
Merger Control
- Charité University Hospital and German Heart Center on the formation of University Heart Center Berlin
- Astellas Pharma on merger control proceedings regarding the sale of its dermatology business to LEO Pharma
- Rhön-Klinikum AG on EU and German (Phase II) merger control proceedings
- Stirling Square Capital Partners on the sale of Cartonplast Group to DBAG
- Shareholders of Prüftechnik Dieter Busch AG on the sale of the company to Fluke Corporation
- Hellman & Friedman and Blackstone Group on their proposed public tender offer for Scout24
Foreign Direct Investment
- Various financial and strategic investors in German, EU, and multi-jurisdictional merger control and foreign investment control proceedings, including:
- Antin
- Astorg
- CVC
- Hg Capital
- J.P. Morgan
- Ortho Clinical Diagnostics
- Silver Lake Partners
- The Carlyle Group
- Triton
- Advanced Micro Devices Inc. on foreign direct investment aspects regarding the acquisition of Xilinx Group
- GIP and KKR on foreign direct investments aspects regarding the investment in Vantage Towers
- Triton on foreign direct investment and merger control aspects regarding the acquisition of RENK
- Hytera on foreign investment and merger control aspects regarding the takeover of Sepura Plc.
- CPPIB coinvesting with KKR in Axel Springer on both merger control and foreign investment control